Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302929 | 0.83 | ATAD2 (0.70) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL303321 | 0.81 | ATAD2 (1.00) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL12415755 | 0.79 | ATAD2 (0.65) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL3589439 | 0.76 | ALDH1A1 (0.69) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL303269 | 0.76 | HTT (1.00) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL2472341 | 0.75 | ATAD2 (0.52) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL504084 | 0.75 | PIK3CD (0.70) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL3589713 | 0.71 | ALDH1A1 (1.00) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL2071153 | 0.71 | ALDH1A1 (0.40) | ATAD2HTTHIF1ATSHRALDH1A1 | |
| SCHEMBL303804 | 0.70 | ATAD2 (0.54) | ATAD2HTTHIF1ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| EP-1910350-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | GCK, GCKR, HK1 | ATAD2 2247/4885HTT 2395/4885HIF1A 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.